Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

医学 心力衰竭 射血分数 达帕格列嗪 内科学 心房颤动 安慰剂 心脏病学 糖尿病前期 2型糖尿病 不利影响 糖尿病 内分泌学 病理 替代医学
作者
Silvio E. Inzucchi,Brian Claggett,Muthiah Vaduganathan,Akshay S. Desai,Pardeep S. Jhund,Rudolf A. de Boer,Adrian F. Hernandez,Mikhail Kosiborod,Carolyn S.P. Lam,Felipe A. Martínez,Sanjiv J. Shah,Subodh Verma,Yaling Han,José Francisco Kerr Saraiva,Olof Bengtsson,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier]
卷期号:10 (12): 869-881 被引量:26
标识
DOI:10.1016/s2213-8587(22)00308-4
摘要

Type 2 diabetes and prediabetes are risk factors for heart failure and adverse heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial showed that dapagliflozin was associated with a reduction in the primary outcome of worsening heart failure or cardiovascular mortality in patients with heart failure with mildly reduced or preserved ejection fraction. We aimed to assess the efficacy and safety of oral dapagliflozin in these patients by their baseline glycaemia categories.DELIVER was an international, multicentre, double-blind, randomised, placebo-controlled trial done in 350 health-care centres and hospitals across 20 countries. Patients aged 40 years or older with New York Heart Association class II-IV, left ventricular ejection fraction of more than 40%, elevated natriuretic peptides (N-terminal pro B-type natriuretic peptide ≥300 pg/mL or ≥600 pg/mL for patients in atrial fibrillation or flutter), and evidence of structural heart disease were randomly assigned (1:1) to 10 mg dapagliflozin or placebo, administered orally, and followed up for a median of 2·3 years (IQR 1·7-2·8). The primary outcome, a composite of time from randomisation to first worsening heart failure events (defined as an unplanned hospitalisation or urgent heart failure visit requiring intravenous therapy) or cardiovascular death, in participants with type 2 diabetes (history of or identified by HbA1c ≥6·5% [48 mmol/mol] at baseline) or prediabetes (HbA1c 5·7 to <6·5% [39 mmol/mol to <48 mmol/mol] at baseline) was compared with those with normoglycaemia (HbA1c <5·7% [39 mmol/mol]). Efficacy of dapagliflozin versus placebo was assessed according to glycaemic status and based on HbA1c as a continuous measure. The full-analysis set comprised all patients who were randomly assigned to study treatment, with patients analysed according to their randomised treatment assignment, irrespective of the treatment received (ie, intention to treat). The safety analysis set comprised patients who were randomly assigned to study treatment and who took at least one dose of investigational product, with patients analysed according to the treatment actually received. This trial is registered with ClinicalTrials.gov, NCT03619213.Between Sept 1, 2018, and Jan 18, 2021, 6263 patients were randomly assigned to oral dapagliflozin (n=3131) or placebo (n=3132). Of these patients, 1175 had normoglycaemia, 1934 had prediabetes, and 3150 had type 2 diabetes and were included in the glycaemia subgroup analysis (3515 [56·2%] of 6263 patients were men and 4435 [70·9%] were White). The incidence rate of the primary outcome was 6·9 per 100 patient-years in the normoglycaemia subgroup (reference), increasing to 7·6 per 100 patient-years in the prediabetes subgroup (hazard ratio 1·09 [95% CI 0·90-1·31]) and 10·1 per 100 patient-years in the type 2 diabetes subgroup (1·46 [1·24-1·73]; p<0·0001 for trend). Dapagliflozin reduced the risk of the primary outcome versus placebo in each subgroup (hazard ratio 0·77 [95% CI 0·57-1·04], log-rank p=0·088, for patients with normoglycaemia, 0·87 [0·69-1·08], log-rank p=0·21, for patients with prediabetes, and 0·81 [0·69-0·95], log-rank p=0·0077, for patients with type 2 diabetes; pinteraction=0·82) and across the continuous HbA1c range (pinteraction=0·85). Volume-related or renal serious adverse events or adverse events leading to discontinuation of the study drug, hypoglycaemia, and amputations were not differentially affected by treatment in any of the glycaemia categories.In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range.AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DAYTOY完成签到,获得积分10
刚刚
1秒前
1秒前
Flllllll完成签到,获得积分10
1秒前
喜悦成威完成签到,获得积分10
1秒前
酷波er应助南佳采纳,获得10
2秒前
2秒前
2秒前
Ava应助yan儿采纳,获得10
2秒前
丘比特应助纯真的莫茗采纳,获得10
2秒前
无花果应助勤恳的素阴采纳,获得10
2秒前
调皮的妙竹完成签到,获得积分10
3秒前
沫沫完成签到,获得积分10
3秒前
wzp发布了新的文献求助10
3秒前
3秒前
程程完成签到,获得积分20
3秒前
打打应助Ll采纳,获得10
3秒前
乐观发卡完成签到,获得积分20
4秒前
安详的帽子完成签到 ,获得积分10
4秒前
4秒前
4秒前
5秒前
vivi猫小咪发布了新的文献求助10
5秒前
Sue完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
Lucas应助南方姑娘采纳,获得10
6秒前
7秒前
zhing完成签到,获得积分10
7秒前
XHH完成签到 ,获得积分0
7秒前
小蘑菇应助sv采纳,获得10
8秒前
欢呼橘子完成签到 ,获得积分10
8秒前
季夏完成签到,获得积分10
8秒前
喜悦成威发布了新的文献求助20
8秒前
大菠萝发布了新的文献求助10
9秒前
9秒前
德德发布了新的文献求助10
9秒前
天天快乐应助Silence采纳,获得10
10秒前
深爱不疑发布了新的文献求助200
10秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527742
求助须知:如何正确求助?哪些是违规求助? 3107867
关于积分的说明 9286956
捐赠科研通 2805612
什么是DOI,文献DOI怎么找? 1540026
邀请新用户注册赠送积分活动 716884
科研通“疑难数据库(出版商)”最低求助积分说明 709762